Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

被引：0

作者：

Sue Ping Thang

Mei Sim Lung

Grace Kong

Michael S. Hofman

Jason Callahan

Michael Michael

Rodney J. Hicks

机构：

[1] Centre for Cancer Imaging,Department of Nuclear Medicine and PET

[2] Peter MacCallum Cancer Centre,undefined

[3] Division of Cancer Medicine,undefined

[4] Neuroendocrine Tumour Unit,undefined

[5] Peter MacCallum Cancer Centre,undefined

[6] Singapore General Hospital,undefined

来源：

European Journal of Nuclear Medicine and Molecular Imaging | 2018年 / 45卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

On page 4 of the original version of this article, the text “Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment” needs to be corrected.

引用

页码：323 / 323

共 48 条

[21] A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)
Duan, H.
Ferri, V
Fisher, G.
Shaheen, S.
Davidzon, G.
Moradi, F.
Nguyen, J.
Franc, B.
Iagaru, A.
Mari, Aparici C.
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 181 - 181
[22] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience
Duan, Heying
Ninatti, Gaia
Girod, Bradley
Ferri, Valentina
Guja, Kip
Song, Hong
Kunz, Pamela
Fisher, George
Iagaru, Andrei
Aparici, Carina Mari
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[23] Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Grade 3 Neuroendocrine Neoplasms: Safety and overall survival in 69 patients
Zhang, J.
Kulkarni, H.
Singh, A.
Niepsch, K.
Mueller, D.
Lehmann, C.
Baum, R.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S587 - S588
[24] Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor.
Kobayashi, Noritoshi
Wild, Damian
Kaul, Felix
Ichikawa, Yasushi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients Single-Institution Retrospective Analysis
Katona, Bryson W.
Roccaro, Giorgio A.
Soulen, Michael C.
Yang, Yu-Xiao
Bennett, Bonita J.
Riff, Brian P.
Glynn, Rebecca A.
Wild, Damian
Nicolas, Guillaume P.
Pryma, Daniel A.
Teitelbaum, Ursina R.
Metz, David C.
PANCREAS, 2017, 46 (09) : 1121 - 1126
[26] THE RELATIONSHIP BETWEEN TUMOUR DOSIMETRY AND OTHER PREDICTIVE AND PROGNOSTIC FACTORS IN PATIENTS WITH UNRESECTABLE NEUROENDOCRINE NEOPLASM (NEN) TREATED WITH PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)
Alipour, Ramin
INTERNAL MEDICINE JOURNAL, 2023, 53 : 31 - 31
[27] Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
Zhang, Jingjing
Kulkarni, Harshad R.
Singh, Aviral
Niepsch, Karin
Mueller, Dirk
Baum, Richard P.
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (03) : 377 - 385
[28] Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review
Wee, C.
Dundar, A.
Packard, A.
Kendi, A. T.
Eiring, R.
Hobday, T.
Halfdanarson, T.
NEUROENDOCRINOLOGY, 2020, 110 : 277 - 277
[29] Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series
Goncalves, I
Burbury, K.
Westerman, D.
Blombery, P.
Tiong, I. S.
Iravani, A.
Ravikumar, A.
Michael, M.
Hofman, M.
Akhurst, T.
Hicks, R.
Kong, G.
NEUROENDOCRINOLOGY, 2019, 108 : 212 - 212
[30] Functional imaging and clinical outcomes in grade 3 neuroendocrine tumors (NETs G3): A single-center retrospective analysis
Laffi, A.
Colandrea, M.
Buonsanti, G.
Bagnardi, V.
Frassoni, S.
Spada, F.
Pisa, E.
Barberis, M.
Rubino, M.
Grana, M. C.
Fazio, N.
ANNALS OF ONCOLOGY, 2021, 32 : S913 - S913

← 1 2 3 4 5 →